Clin2
NCT07284667Possibly a fitRecruiting

A new medicine for depression that hasn't improved with other treatments

Major Depressive Disorder (MDD)Depressive Disorder, Treatment-Resistant

Part of Mental health clinical trials.

This trial tests a new medicine called ACP-211 in adults with major depression who have not gotten enough relief from at least two previous antidepressants. The goal is to see if it can help when other treatments have not worked well.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
153 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old.
  • You have been diagnosed with major depressive disorder.
  • You have tried at least two antidepressants in the past that did not work well enough.
  • You are currently taking an antidepressant at a stable dose.
  • You are not currently at high risk of suicide or have a recent suicide attempt.
  • You do not have certain other mental health conditions like bipolar disorder, schizophrenia, or OCD.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07226661Recruiting· Phase 2
Study of an investigational drug for depression

This trial tests an investigational medication for adults with major depressive disorder who are currently taking an antidepressant but still have symptoms. It aims to see if adding this new drug can improve mood better than a placebo.

Garden Grove, California
NCT07741240Not yet recruiting· Phase 3
New antidepressant study for adults with major depression

This study tests an investigational drug called KH607 for adults with major depressive disorder (MDD). It aims to see if the drug can safely and effectively reduce depression symptoms.

NCT05641623Recruiting· Phase 2
Study drug for depression that didn’t improve on common antidepressants

This Phase 2 trial tests OSU6162 added to an SSRI or SNRI in people whose major depression did not improve enough after trying specific antidepressants for at least 6 weeks. It may help reduce depression symptoms when standard treatments haven’t worked well.

Lund, Skåne County
NCT06827431Not yet recruiting· Phase 3
Testing ammoxetine for depression

This trial tests an investigational medication called ammoxetine for people with moderate to severe depression. It aims to see if the drug can reduce depressive symptoms and is for those who haven't had success with certain other antidepressants.

NCT06830044Recruiting· Phase 3
Adding an experimental drug for major depression

This trial tests if adding a new medicine called milsaperidone can help people with major depression who haven't gotten enough relief from their current antidepressant. It aims to see if the combination works better than the antidepressant alone.

Phoenix, Arizona
NCT06511908Recruiting· Phase 2
Testing a new ketamine-like drug for hard-to-treat depression

This study tests a new experimental drug (2R,6R)-HNK, a chemical related to ketamine, given by IV infusion to see if it can help people with depression that hasn't improved with other treatments. The goal is to find a new option for people who have not found relief from standard antidepressants.

Bethesda, Maryland

Hear when a new Depressive Disorder, Treatment-Resistant trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.